PharmGKB summary: fluoropyrimidine pathways
- PMID: 20601926
- PMCID: PMC3098754
- DOI: 10.1097/FPC.0b013e32833c6107
PharmGKB summary: fluoropyrimidine pathways
Figures


Similar articles
-
Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.Ann Oncol. 2008 Nov;19(11):1980-1. doi: 10.1093/annonc/mdn662. Ann Oncol. 2008. PMID: 18952760 Clinical Trial. No abstract available.
-
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.Clin Colorectal Cancer. 2007 Mar;6(6):407-22. doi: 10.1016/s1533-0028(11)70480-7. Clin Colorectal Cancer. 2007. PMID: 17539192 Review. No abstract available.
-
Capecitabine in gastric cancer.Drugs Today (Barc). 2008 Aug;44(8):629-40. doi: 10.1358/dot.2008.44.8.1244748. Drugs Today (Barc). 2008. PMID: 18846273 Review.
-
Capecitabine in advanced gastric cancer.Expert Opin Pharmacother. 2007 Nov;8(16):2851-61. doi: 10.1517/14656566.8.16.2851. Expert Opin Pharmacother. 2007. PMID: 17956204 Review.
-
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.Br J Cancer. 2004 Aug 16;91(4):613-7. doi: 10.1038/sj.bjc.6601973. Br J Cancer. 2004. PMID: 15280932 Free PMC article. Review.
Cited by
-
Fluoropyrimidine Toxicities and DPYD Genotyping: A Clinical Case.Cureus. 2024 Jul 4;16(7):e63814. doi: 10.7759/cureus.63814. eCollection 2024 Jul. Cureus. 2024. PMID: 39099950 Free PMC article.
-
Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study.Pharmaceutics. 2021 Nov 29;13(12):2036. doi: 10.3390/pharmaceutics13122036. Pharmaceutics. 2021. PMID: 34959317 Free PMC article.
-
Transient Coma and Signs of Encephalopathy Related to 5-Fluorouracil and Carboplatin: A Case Report.Case Rep Oncol. 2023 Jul 13;16(1):525-531. doi: 10.1159/000531472. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 37485017 Free PMC article.
-
Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration.Pharm Res. 2023 Sep;40(9):2177-2194. doi: 10.1007/s11095-023-03585-y. Epub 2023 Aug 23. Pharm Res. 2023. PMID: 37610618
-
PharmGKB: the Pharmacogenomics Knowledge Base.Methods Mol Biol. 2013;1015:311-20. doi: 10.1007/978-1-62703-435-7_20. Methods Mol Biol. 2013. PMID: 23824865 Free PMC article.
References
-
- Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16:215–237. - PubMed
-
- Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–338. - PubMed
-
- Hwang JJ, Marshall JL. Capecitabine: fulfilling the promise of oral chemotherapy. Expert Opin Pharmacother. 2002;3:733–743. - PubMed
-
- Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–1281. - PubMed
-
- Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res. 2008;14:8–13. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources